Embecta

Roche acquires Poseida Therapeutics for up to $1.5B, expanding into CAR-T therapies. U.S. overdose deaths decline by 14.5% to 97,000 over 12 months. Arrowhead Pharmaceuticals licenses programs to Sarepta Therapeutics for $500M upfront and $325M in equity. Recordati and Angelini Pharma consider merger to form Europe's largest generics group. FDA approves BridgeBio's heart drug for transthyretin amyloidosis, challenging Pfizer's tafamidis. Novo Holdings expected to receive EU approval for $16.5B acquisition of Catalent Pharma Solutions. Amgen's obesity drug MariTide shows 20% weight loss in Phase II. Anavex Life Sciences submits MAA to EMA for Alzheimer's treatment. Biohaven's muscle drug fails in SMA study. embecta reports strong revenues of $1.12B, discontinues insulin patch pump. Axsome Therapeutics reports positive Phase 3 results for narcolepsy drug AXS-12. Kronos Bio to lay off 83% of workforce. PTC Therapeutics sells Rare Pediatric Disease Priority Review Voucher for $150M. EMA launches medicine shortages monitoring platform. Alector lays off 41 employees after Alzheimer's drug AL002 fails. Grifols seeks to refinance €1.4B in debt. Roche's cancer drug tiragolumab fails Phase 3 trial.

Embecta cancels insulin patch pump program after FDA clearance, citing cost reduction and market competitiveness issues. The company plans to focus on core business and debt reduction, expecting pre-tax charges up to $45 million in fiscal year 2025.

FDA approves dupilumab for COPD, xanomeline and trospium chloride for schizophrenia, levacetylleucine for Niemann-Pick disease type C, FluMist for self-administered flu prevention, benralizumab for eosinophilic granulomatosis with polyangiitis, lebrikizumab-lbkz for atopic dermatitis, OTC hearing aid software for mild to moderate hearing loss, DaylightRX for generalized anxiety disorder, a disposable insulin patch pump for T1D and T2D, and an updated Novavax COVID-19 vaccine.

FDA clears digital therapeutic DaylightRX for GAD, approves updated Novavax COVID-19 vaccine, and clears Embecta's disposable insulin patch pump. Big 3 PBMs control US drug supply chain, NCPA urges CMS for PBM protection, and Cigna's Express Scripts sues FTC. FTC counters with lawsuit against 'Big 3' PBMs for insulin price inflation. Abbott's OTC Lingo CGM available, Vaxcyte announces positive data for 31-valent pneumococcal vaccine, and AI-optimized cash pricing aids pharmacies.

Embecta's new disposable insulin delivery system, approved by the FDA, features a tubeless patch device with a 300-unit insulin reservoir, designed for type 1 and type 2 diabetes patients. The system includes a Bluetooth-enabled controller and aims to improve diabetes care, with future plans for a closed-loop version.

FDA clears tubeless insulin patch pump for type 1 and type 2 diabetes, featuring a 300 U insulin reservoir for up to 3 days use.

FDA grants EUA to Novavax's updated COVID-19 vaccine for individuals aged 12+, available in U.S. pharmacies. FDA clears first digital therapeutic, DaylightRX, for GAD treatment. Embecta receives 510(k) clearance for disposable insulin patch pump for T1D and T2D patients. FDA authorizes BioVie's IND for phase 2 trial of bezisterim to treat neurological symptoms of post-COVID-19 condition.